University of Cambridge > Talks.cam > Lectures in Cancer Biology and Medicine > The challenges in therapeutic targeting of the RAF-MEK-ERK signalling pathway

The challenges in therapeutic targeting of the RAF-MEK-ERK signalling pathway

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Louisa Bellis.

The ERK1 /2 signalling pathway is de-regulated in a variety of cancers due to mutations in RAS (especially KRAS ), BRAF and MEK . This has led to the development of a variety of protein kinase inhibitors that target BRAF , MEK or ERK . Indeed, BRAF and MEK inhibitors are now approved for treatment of melanomas harbouring BRAFV600E /K mutations. This talk will highlight some of the challenges that these kinase inhibitors face – especially intrinsic and acquired resistance – as well as some solutions.

This talk is part of the Lectures in Cancer Biology and Medicine series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.

 

© 2006-2020 Talks.cam, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity